• Je něco špatně v tomto záznamu ?

Mikrovoltový T-ware alternas: je přínosný pro indikaci ICD?
[ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention]

Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH 2nd, Sethuraman B, Dettmer MM, Rosenbaum DS

. 2009 ; 3 (4) : 34-35.

Jazyk čeština Země Česko

Typ dokumentu klinické zkoušky, srovnávací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc09002355

Because risk stratification with electrophysiological study (EPS) improves efficiency but is invasive, we sought to determine whether noninvasive microvolt T-wave alternans (MTWA) testing could identify patients who benefit from implantable cardioverter-defibrillators (ICDs) as well as EPS. BACKGROUND: Prevention of sudden cardiac death on the basis of left ventricular ejection fraction (LVEF) alone is inefficient, because most ICDs never deliver therapy. METHODS: The ABCD (Alternans Before Cardioverter Defibrillator) trial is a multicenter prospective study that enrolled patients with ischemic cardiomyopathy (LVEF < or =0.40) and nonsustained ventricular tachycardia. All patients underwent MTWA and EPS. ICDs were mandated if either test was positive. RESULTS: Of 566 patients followed for a median of 1.9 years, 39 (7.5%) met the primary end point of appropriate ICD discharge or sudden death at 1 year. As hypothesized, primary analysis showed that MTWA achieved 1-year positive (9%) and negative (95%) predictive values that were comparable to EPS (11% and 95%, respectively). In addition, secondary analysis showed that at the pre-specified 1-year end point, event rates were significantly higher in patients with both a positive MTWA-directed strategy (hazard ratio: 2.1, p = 0.03) and a positive EPS-directed strategy (hazard ratio: 2.4, p = 0.007). Moreover, the event rate in patients with both negative MTWA test and EPS was lower than in those with 2 positive tests (2% vs. 12%; p = 0.017). CONCLUSIONS: The ABCD study is the first trial to use MTWA to guide prophylactic ICD insertion. Risk stratification strategies using noninvasive MTWA versus invasive EPS are comparable at 1 year and complementary when applied in combination. Strategies employing MTWA, EPS, or both might identify subsets of patients least likely to benefit from ICD insertion. (Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-Threatening Heart Rhythms [ABCD Study]; NCT00187291).

ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention

Recenze v:

Komentář [k článku Mikrovoltový T-ware alternas: je přínosný pro indikaci ICD?].

000      
00000naa 2200000 a 4500
001      
bmc09002355
003      
CZ-PrNML
005      
20111210152434.0
008      
091105s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Costantini, Otto
245    10
$a Mikrovoltový T-ware alternas: je přínosný pro indikaci ICD? / $c Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH 2nd, Sethuraman B, Dettmer MM, Rosenbaum DS
246    11
$a ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention
314    __
$a The Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland ocostantini@metrohealth.org
520    9_
$a Because risk stratification with electrophysiological study (EPS) improves efficiency but is invasive, we sought to determine whether noninvasive microvolt T-wave alternans (MTWA) testing could identify patients who benefit from implantable cardioverter-defibrillators (ICDs) as well as EPS. BACKGROUND: Prevention of sudden cardiac death on the basis of left ventricular ejection fraction (LVEF) alone is inefficient, because most ICDs never deliver therapy. METHODS: The ABCD (Alternans Before Cardioverter Defibrillator) trial is a multicenter prospective study that enrolled patients with ischemic cardiomyopathy (LVEF < or =0.40) and nonsustained ventricular tachycardia. All patients underwent MTWA and EPS. ICDs were mandated if either test was positive. RESULTS: Of 566 patients followed for a median of 1.9 years, 39 (7.5%) met the primary end point of appropriate ICD discharge or sudden death at 1 year. As hypothesized, primary analysis showed that MTWA achieved 1-year positive (9%) and negative (95%) predictive values that were comparable to EPS (11% and 95%, respectively). In addition, secondary analysis showed that at the pre-specified 1-year end point, event rates were significantly higher in patients with both a positive MTWA-directed strategy (hazard ratio: 2.1, p = 0.03) and a positive EPS-directed strategy (hazard ratio: 2.4, p = 0.007). Moreover, the event rate in patients with both negative MTWA test and EPS was lower than in those with 2 positive tests (2% vs. 12%; p = 0.017). CONCLUSIONS: The ABCD study is the first trial to use MTWA to guide prophylactic ICD insertion. Risk stratification strategies using noninvasive MTWA versus invasive EPS are comparable at 1 year and complementary when applied in combination. Strategies employing MTWA, EPS, or both might identify subsets of patients least likely to benefit from ICD insertion. (Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-Threatening Heart Rhythms [ABCD Study]; NCT00187291).
650    _2
$a financování organizované $7 D005381
650    _2
$a senioři $7 D000368
650    _2
$a srdeční elektrofyziologie $7 D054849
650    _2
$a kardiomyopatie $x terapie $7 D009202
650    _2
$a náhlá srdeční smrt $x prevence a kontrola $7 D016757
650    _2
$a defibrilátory implantabilní $7 D017147
650    _2
$a elektrokardiografie $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ischemická choroba srdeční $x terapie $7 D017202
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a komorová tachykardie $x terapie $7 D017180
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Hohnloser, S. H.
700    1_
$a Kirk, M. M.
700    1_
$a Lerman, B. B.
700    1_
$a Baker, J. H.
700    1_
$a Sethuraman, B.
700    1_
$a Dettmer, M. M.
700    1_
$a Rosenbaum, D. S.
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 3, č. 4 (2009), s. 34-35 $x 1213-2586
787    18
$w bmc09002357 $i Recenze v: $t Komentář [k článku Mikrovoltový T-ware alternas: je přínosný pro indikaci ICD?]
910    __
$a ABA008 $b B 2242 $c 407 a $y 9
990    __
$a 20091105110109 $b ABA008
991    __
$a 20091201103508 $b ABA008
999    __
$a ok $b bmc $g 691526 $s 553425
BAS    __
$a 3
BMC    __
$a 2009 $b 3 $c 4 $d 34-35 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2009-34/mkme

Najít záznam

Citační ukazatele

Možnosti archivace